ISCHEMIC STROKE / THERAPY

Acute stroke in anticoagulated patient

Created 18/04/2022, last revision 25/05/2022

  • anticoagulants have become the mainstay of stroke prevention in patients with atrial fibrillation or other potential sources of cardioembolism
  • however, even with this therapy (including DOACs), ischemic stroke can occur, and we then address 2 basic scenarios in the acute phase:
    • the patient is a candidate for recanalization therapy
      • can the effect of an anticoagulant drug be neutralized and IVT administered?
      • choose direct thrombectomy?
    • the patient is not a candidate for recanalization therapy
      • continue anticoagulation therapy?
      • discontinue therapy for 7-14 days and then restart?
      • when discontinuing oral anticoagulation, should we start ASA or LMWH temporarily, and at what dose?
  • before restarting the anticoagulant therapy, analyze its previous failure
    • poorly adjusted warfarin with low INR?
    • underdosing or discontinuation of DOACs?
    • other stroke mechanisms? (dissection, vasculitis, etc.)
Acute stroke in anticoagulated patient

The patient is a candidate for recanalization therapy

The patient is NOT a candidate for recanalization therapy

  • initiation of anticoagulation in the early stages of stroke is, in general, not recommended
  • continuation of effective anticoagulation therapy reduces the risk of recurrence but also increases the risk of hemorrhagic transformation of ischemia (HTI)
  • the risk of recurrence of cardioembolic stroke in the first 14 days is relatively low according to studies (about 5-8%), and the potential benefit of early anticoagulation is negated by a higher incidence of hemorrhage
    • according to the IST trial (UFH vs. placebo), the risk of recurrence in the heparin arm was about 2.3 vs. 4.9%/14 days, but the incidence of ICH was higher (2.8 vs. 0.4%) ⇒ no net benefit
    • in the HAEST trial, LMWH vs. aspirin was tested – the difference in stroke recurrence rate was non-significant (approx. 8% in 14 days in both groups)
  • rapid neutralization of the anticoagulant effect may reduce the risk of HTI compared with gradual withdrawal; however, studies are lacking
  • ASA bridging
    • according to the IST and CAST trials, the absolute reduction in stroke recurrence is approx. 1% (similar to patients without AFib). ASA probably does not substantially reduce the risk of cardioembolism, but either it does not increase the risk of hemorrhage
    • a meta-analysis of 3 trials (IST, CAST, and HAEST) proved little benefit with ASA and no benefit with heparin
  • LMWH bridging
    • not at therapeutic doses
    • used only as mini-heparinisation in VTE prophylaxis; prefer IPC for large stroke → VTE prevention
  • the decision, whether to discontinue anticoagulation or when it should be restarted, is highly individual
  • when restarting therapy, the current DOAC or another drug can be used – the RENO-EXTENT trial showed similar recurrence rates for both strategies
Content available only for logged-in subscribers (registration will be available soon)
icon-angle icon-bars icon-times